162 related articles for article (PubMed ID: 3112375)
1. Polyfunctional properties of hybridoma lupus anticoagulant antibodies.
Rauch J; Tannenbaum H; Senécal JL; Janoff AS; Cullis PR; Frojmovic MM
J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():132-7. PubMed ID: 3112375
[TBL] [Abstract][Full Text] [Related]
2. Lupus anticoagulant and antiplatelet properties of human hybridoma autoantibodies.
Rauch J; Meng QH; Tannenbaum H
J Immunol; 1987 Oct; 139(8):2598-604. PubMed ID: 3116088
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal hybridoma anti-cardiolipin antibodies from SLE mice.
Ichikawa K; Shimada K; Nawata Y; Ishii T; Tomioka H; Yoshida S; Koike T
Clin Exp Immunol; 1988 Oct; 74(1):110-4. PubMed ID: 3146452
[TBL] [Abstract][Full Text] [Related]
4. Specific and shared idiotypes found on hybridoma anti-DNA autoantibodies derived from rheumatoid arthritis and systemic lupus erythematosus patients.
Rauch J; Massicotte H; Tannenbaum H
J Immunol; 1985 Oct; 135(4):2385-92. PubMed ID: 3875652
[TBL] [Abstract][Full Text] [Related]
5. Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets.
Hasselaar P; Derksen RH; Blokzijl L; de Groot PG
Thromb Haemost; 1990 Apr; 63(2):169-73. PubMed ID: 2114042
[TBL] [Abstract][Full Text] [Related]
6. Human-human hybridoma autoantibodies with both anti-DNA and rheumatoid factor activities.
Rauch J; Tannenbaum H; Straaton K; Massicotte H; Wild J
J Clin Invest; 1986 Jan; 77(1):106-12. PubMed ID: 3511088
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids.
Rauch J; Tannenbaum M; Janoff AS
Thromb Haemost; 1989 Nov; 62(3):892-6. PubMed ID: 2512678
[TBL] [Abstract][Full Text] [Related]
8. Anticardiolipin antibodies: their presence as a marker for lupus anticoagulant in pregnancy.
Pattison NS; McKay EJ; Liggins GC; Lubbe WF
N Z Med J; 1987 Feb; 100(817):61-4. PubMed ID: 3103033
[TBL] [Abstract][Full Text] [Related]
9. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
[TBL] [Abstract][Full Text] [Related]
10. Antiphospholipid antibodies: an elderly statesman Dons new garments.
Harris EN; Hughes GR; Gharavi AE
J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():208-13. PubMed ID: 3112376
[TBL] [Abstract][Full Text] [Related]
11. The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome.
Arnout J
Verh K Acad Geneeskd Belg; 2000; 62(5):353-72. PubMed ID: 11144685
[TBL] [Abstract][Full Text] [Related]
12. The activated seven lupus anticoagulant assay detects clinically significant antibodies.
Moore GW; Rangarajan S; Savidge GF
Clin Appl Thromb Hemost; 2008 Jul; 14(3):332-7. PubMed ID: 17895508
[TBL] [Abstract][Full Text] [Related]
13. Antiphospholipid antibodies: a disease marker in 25 patients with antinuclear antibody negative systemic lupus erythematosus (SLE). Comparison with a group of 91 patients with antinuclear antibody positive SLE.
Meyer O; Piette JC; Bourgeois P; Fallas P; Bletry O; Jungers P; Kahn MF; Godeau P; Ryckewaert A
J Rheumatol; 1987 Jun; 14(3):502-6. PubMed ID: 3114485
[TBL] [Abstract][Full Text] [Related]
14. Anticardiolipin antibodies possess anticoagulant activity which is blocked by a monoclonal antibody against a cross reacting idiotype of antiphospholipid antibodies.
Valesini G; Violi F; Ferro D; Quintarelli C; Falco M; Tincani A; Balestrieri G; Balsano F
Clin Exp Rheumatol; 1989; 7(6):615-8. PubMed ID: 2515018
[TBL] [Abstract][Full Text] [Related]
15. Antibody to cardiolipin, lupus anticoagulant, and fetal death.
Lockshin MD; Qamar T; Druzin ML; Goei S
J Rheumatol; 1987 Apr; 14(2):259-62. PubMed ID: 3110418
[TBL] [Abstract][Full Text] [Related]
16. Antiphospholipid antibodies: a review.
Harris EN; Gharavi AE; Asherson RA; Hughes GR
Eur J Rheumatol Inflamm; 1984; 7(1):5-8. PubMed ID: 6443722
[No Abstract] [Full Text] [Related]
17. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems.
Rauch J; Tannenbaum M; Tannenbaum H; Ramelson H; Cullis PR; Tilcock CP; Hope MJ; Janoff AS
J Biol Chem; 1986 Jul; 261(21):9672-7. PubMed ID: 3733693
[TBL] [Abstract][Full Text] [Related]
18. Immunological and molecular analysis of three monoclonal lupus anticoagulant antibodies from a patient with systemic lupus erythematosus.
Lai CJ; Rauch J; Cho CS; Zhao Y; Chukwuocha RU; Chen PP
J Autoimmun; 1998 Feb; 11(1):39-51. PubMed ID: 9480722
[TBL] [Abstract][Full Text] [Related]
19. [Relation of antiphospholipid antibodies to thrombotic phenomena and clinical activity of systemic lupus erythematosus].
Font J; Cervera R; Casals FJ; Bové A; Guerrero A; López-Soto A; Ingelmo M; Urbano-Márquez A
Med Clin (Barc); 1988 Mar; 90(12):490-3. PubMed ID: 3134583
[No Abstract] [Full Text] [Related]
20. Antinuclear antibody-negative systemic lupus erythematosus (SLE) and severe renal involvement: close correlation between disease activity and appearance of circulating anticoagulant.
Raz E; Michaeli J; Rosenmann E; Rubinow A; Popovtzer MM
Isr J Med Sci; 1988 Feb; 24(2):105-8. PubMed ID: 3128493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
